Two Boston-area biotech startups are shrugging off the recent stock market volatility as they press forward with plans for initial public stock offerings. Genetic therapies company Homology Medicines and cell therapy developer Unum Therapeutics each filed IPO paperwork with regulators late Friday. Unum’s filing revealed that two patients died in a Phase 1 trial late last year. The FDA placed a hold on the trial in December and lifted it last month.
Homology set a preliminary goal of raising $100 million. The Bedford, MA, company has applied for a listing on the Nasdaq Global Market under the stock symbol “FIXX.” Unum,… Read more »
UNDERWRITERS AND PARTNERS